Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

9.426 -0.494 (-4.98%)
Streaming Delayed Price Updated: 12:52 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. 
Via Benzinga
Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.31% to 33,309.28 while the NASDAQ fell 1.09% to 13,042.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
Via Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
Via Benzinga
Why Shares of Arcutis Biotherapeutics Fell This Week
The company released phase 3 trial results for an atopic dermatitis cream. 
Via The Motley Fool
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching on Friday morning! 
Via InvestorPlace
Arcutis Announces Pricing of $100 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
Via Benzinga
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis 
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its... 
Via Benzinga
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
US Stocks Mostly Higher; RH Posts Upbeat Earnings
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
3 Biotech Stocks Due for a Massive Short Squeeze
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters. 
Via InvestorPlace
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.